Loader

Pathways

PathWhiz ID Pathway Meta Data

PW336795

Pw336795 View Pathway
metabolic

2-Oxoglutarate Decarboxylation to Succinyl-CoA

Tatumella ptyseos ATCC 33301
2-oxoglutarate dehydrogenase complex is consisted of oxoglutarate decarboxylase, dihydrolipoyl succinyltransferase and dihydrolipoyl dehydrogenase), which is a rate-limiting enzyme of the citric acid cycle (TCA cycle) in prokaryote. The reaction that catalyzed by 2-oxoglutarate dehydrogenase complex can be generalized as 2-oxoglutarate + coenzyme A + NAD+ → succinyl-CoA + CO2 + NADH. During the OGDHC reaction cycle, 2-oxoglutarate is bound and decarboxylated by E1(o), a thiamin-diphosphate cofactor containing enzyme. The succinyl group is transferred to the lipoyl domain of E2(o) where it is carried to the active site and transferred to coenzyme A, forming succinyl-CoA. During this transfer the lipoyl group is reduced to dihydrolipoyl. The succinyl-CoA is released and the lipoyl domain of E2(o) is oxidized by E3 via transfer of protons to NAD, forming NADH and regenerating the lipoyl group back to lipoyllysine for another cycle. Under aerobic growth conditions the OGDHC not only catalyzes a key reaction in the TCA cycle, it also provides succinyl-CoA for methionine and lysine biosynthesis, the latter pathway also leading to peptidoglycan biosynthesis. The synthesis of the OGDHC is repressed by anaerobiosis and is also subject to glucose repression. It is induced by aerobic growth on acetate. (EcoCyc)
BioPAX SVG SBGN SBML PWML All files (.zip)

Creator: Julia Wakoli

Created On: October 23, 2024 at 13:14

Last Updated: October 23, 2024 at 13:14

PW336834

Pw336834 View Pathway
metabolic

2-Oxoglutarate Decarboxylation to Succinyl-CoA

Paenibacillus lactis 154
2-oxoglutarate dehydrogenase complex is consisted of oxoglutarate decarboxylase, dihydrolipoyl succinyltransferase and dihydrolipoyl dehydrogenase), which is a rate-limiting enzyme of the citric acid cycle (TCA cycle) in prokaryote. The reaction that catalyzed by 2-oxoglutarate dehydrogenase complex can be generalized as 2-oxoglutarate + coenzyme A + NAD+ → succinyl-CoA + CO2 + NADH. During the OGDHC reaction cycle, 2-oxoglutarate is bound and decarboxylated by E1(o), a thiamin-diphosphate cofactor containing enzyme. The succinyl group is transferred to the lipoyl domain of E2(o) where it is carried to the active site and transferred to coenzyme A, forming succinyl-CoA. During this transfer the lipoyl group is reduced to dihydrolipoyl. The succinyl-CoA is released and the lipoyl domain of E2(o) is oxidized by E3 via transfer of protons to NAD, forming NADH and regenerating the lipoyl group back to lipoyllysine for another cycle. Under aerobic growth conditions the OGDHC not only catalyzes a key reaction in the TCA cycle, it also provides succinyl-CoA for methionine and lysine biosynthesis, the latter pathway also leading to peptidoglycan biosynthesis. The synthesis of the OGDHC is repressed by anaerobiosis and is also subject to glucose repression. It is induced by aerobic growth on acetate. (EcoCyc)
BioPAX SVG SBGN SBML PWML All files (.zip)

Creator: Julia Wakoli

Created On: October 23, 2024 at 13:56

Last Updated: October 23, 2024 at 13:56

PW336827

Pw336827 View Pathway
metabolic

2-Oxoglutarate Decarboxylation to Succinyl-CoA

Vibrio fluvialis PG41
2-oxoglutarate dehydrogenase complex is consisted of oxoglutarate decarboxylase, dihydrolipoyl succinyltransferase and dihydrolipoyl dehydrogenase), which is a rate-limiting enzyme of the citric acid cycle (TCA cycle) in prokaryote. The reaction that catalyzed by 2-oxoglutarate dehydrogenase complex can be generalized as 2-oxoglutarate + coenzyme A + NAD+ → succinyl-CoA + CO2 + NADH. During the OGDHC reaction cycle, 2-oxoglutarate is bound and decarboxylated by E1(o), a thiamin-diphosphate cofactor containing enzyme. The succinyl group is transferred to the lipoyl domain of E2(o) where it is carried to the active site and transferred to coenzyme A, forming succinyl-CoA. During this transfer the lipoyl group is reduced to dihydrolipoyl. The succinyl-CoA is released and the lipoyl domain of E2(o) is oxidized by E3 via transfer of protons to NAD, forming NADH and regenerating the lipoyl group back to lipoyllysine for another cycle. Under aerobic growth conditions the OGDHC not only catalyzes a key reaction in the TCA cycle, it also provides succinyl-CoA for methionine and lysine biosynthesis, the latter pathway also leading to peptidoglycan biosynthesis. The synthesis of the OGDHC is repressed by anaerobiosis and is also subject to glucose repression. It is induced by aerobic growth on acetate. (EcoCyc)
BioPAX SVG SBGN SBML PWML All files (.zip)

Creator: Julia Wakoli

Created On: October 23, 2024 at 13:48

Last Updated: October 23, 2024 at 13:48

PW336086

Pw336086 View Pathway
metabolic

2-Oxoglutarate Decarboxylation to Succinyl-CoA

Bacteroides clarus YIT 12056
2-oxoglutarate dehydrogenase complex is consisted of oxoglutarate decarboxylase, dihydrolipoyl succinyltransferase and dihydrolipoyl dehydrogenase), which is a rate-limiting enzyme of the citric acid cycle (TCA cycle) in prokaryote. The reaction that catalyzed by 2-oxoglutarate dehydrogenase complex can be generalized as 2-oxoglutarate + coenzyme A + NAD+ → succinyl-CoA + CO2 + NADH. During the OGDHC reaction cycle, 2-oxoglutarate is bound and decarboxylated by E1(o), a thiamin-diphosphate cofactor containing enzyme. The succinyl group is transferred to the lipoyl domain of E2(o) where it is carried to the active site and transferred to coenzyme A, forming succinyl-CoA. During this transfer the lipoyl group is reduced to dihydrolipoyl. The succinyl-CoA is released and the lipoyl domain of E2(o) is oxidized by E3 via transfer of protons to NAD, forming NADH and regenerating the lipoyl group back to lipoyllysine for another cycle. Under aerobic growth conditions the OGDHC not only catalyzes a key reaction in the TCA cycle, it also provides succinyl-CoA for methionine and lysine biosynthesis, the latter pathway also leading to peptidoglycan biosynthesis. The synthesis of the OGDHC is repressed by anaerobiosis and is also subject to glucose repression. It is induced by aerobic growth on acetate. (EcoCyc)
BioPAX SVG SBGN SBML PWML All files (.zip)

Creator: Julia Wakoli

Created On: October 22, 2024 at 15:16

Last Updated: October 22, 2024 at 15:16

PW336098

Pw336098 View Pathway
metabolic

2-Oxoglutarate Decarboxylation to Succinyl-CoA

Bacteroides stercoris ATCC 43183
2-oxoglutarate dehydrogenase complex is consisted of oxoglutarate decarboxylase, dihydrolipoyl succinyltransferase and dihydrolipoyl dehydrogenase), which is a rate-limiting enzyme of the citric acid cycle (TCA cycle) in prokaryote. The reaction that catalyzed by 2-oxoglutarate dehydrogenase complex can be generalized as 2-oxoglutarate + coenzyme A + NAD+ → succinyl-CoA + CO2 + NADH. During the OGDHC reaction cycle, 2-oxoglutarate is bound and decarboxylated by E1(o), a thiamin-diphosphate cofactor containing enzyme. The succinyl group is transferred to the lipoyl domain of E2(o) where it is carried to the active site and transferred to coenzyme A, forming succinyl-CoA. During this transfer the lipoyl group is reduced to dihydrolipoyl. The succinyl-CoA is released and the lipoyl domain of E2(o) is oxidized by E3 via transfer of protons to NAD, forming NADH and regenerating the lipoyl group back to lipoyllysine for another cycle. Under aerobic growth conditions the OGDHC not only catalyzes a key reaction in the TCA cycle, it also provides succinyl-CoA for methionine and lysine biosynthesis, the latter pathway also leading to peptidoglycan biosynthesis. The synthesis of the OGDHC is repressed by anaerobiosis and is also subject to glucose repression. It is induced by aerobic growth on acetate. (EcoCyc)
BioPAX SVG SBGN SBML PWML All files (.zip)

Creator: Julia Wakoli

Created On: October 22, 2024 at 15:24

Last Updated: October 22, 2024 at 15:24

PW002096

Pw002096 View Pathway
metabolic

2-O-alpha-Mannosyl-D-glycerate Degradation

Escherichia coli
2-O-α-Mannosyl-D-glycerate (MG; also named as Alpha-Mannosylglycerate) is an organic compound that will affect the osmosis in hyperthermophilic archaea and bacteria. In E.coli, 2-O-α-mannosyl-D-glycerate PTS permease (mngA) import MG into cell, and then phosphorylate MG to 2-O-(6-phospho-α-mannosyl)-D-glycerate by phosphocarrier protein HPr. 2-O-(6-phospho-α-mannosyl)-D-glycerate is converted to glyceric acid as well as mannose 6-phosphate by alpha-mannosidase mngB. Finally, glyceric acid is catalyzed to 2-Phospho-D-glyceric acid with ATP as energy source by Glycerate kinase 2. E.coli can't use MG as osmotic stress protection, but it can use MG as a carbon source.
BioPAX SVG SBGN SBML PWML All files (.zip)

Creator: Ana Marcu

Created On: October 13, 2015 at 17:28

Last Updated: October 13, 2015 at 17:28

PW000061

Pw000061 View Pathway
disease

2-Methyl-3-hydroxybutyryl-CoA Dehydrogenase Deficiency

Homo sapiens
2-Methyl-3-hydroxybutyryl CoA dehydrogenase deficiency (Hydroxyl-CoA dehydrogenase deficiency; MHBD) is a rare inborn disease of metabolism caused by a mutation in the HSD17B10 gene which codes for 3-hydroxyacyl-CoA dehydrogenase type-2. A deficiency in this enzyme results in accumulation of L-lactic acid in blood, spinal fluid, and urine; 2-ethylhydracrylic acid, 2-methyl-3-hydroxybutyric acid, and tiglylglycine in urine. Symptoms include cerebal atrophy, motor and mental retardation, overactivity and behavior issues, seizures and progressive neurological defects leading to early death. Treatment includes a high carbohydrate and low protein diet.
BioPAX SVG SBGN SBML PWML All files (.zip)

Creator: WishartLab

Created On: August 01, 2013 at 15:52

Last Updated: August 01, 2013 at 15:52

PW127223

Pw127223 View Pathway
disease

2-Methyl-3-hydroxybutyryl-CoA Dehydrogenase Deficiency

Homo sapiens
2-Methyl-3-hydroxybutyryl CoA dehydrogenase deficiency (Hydroxyl-CoA dehydrogenase deficiency; MHBD) is a rare inborn disease of metabolism caused by a mutation in the HSD17B10 gene which codes for 3-hydroxyacyl-CoA dehydrogenase type-2. A deficiency in this enzyme results in accumulation of L-lactic acid in blood, spinal fluid, and urine; 2-ethylhydracrylic acid, 2-methyl-3-hydroxybutyric acid, and tiglylglycine in urine. Symptoms include cerebal atrophy, motor and mental retardation, overactivity and behavior issues, seizures and progressive neurological defects leading to early death. Treatment includes a high carbohydrate and low protein diet.
BioPAX SVG SBGN SBML PWML All files (.zip)

Creator: Ray Kruger

Created On: November 15, 2022 at 11:02

Last Updated: November 15, 2022 at 11:02

PW121916

Pw121916 View Pathway
disease

2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency

Rattus norvegicus
2-Methyl-3-hydroxybutyryl CoA dehydrogenase deficiency (Hydroxyl-CoA dehydrogenase deficiency; MHBD) is a rare inborn disease of metabolism caused by a mutation in the HSD17B10 gene which codes for 3-hydroxyacyl-CoA dehydrogenase type-2. A deficiency in this enzyme results in accumulation of L-lactic acid in blood, spinal fluid, and urine; 2-ethylhydracrylic acid, 2-methyl-3-hydroxybutyric acid, and tiglylglycine in urine. Symptoms include cerebal atrophy, motor and mental retardation, overactivity and behavior issues, seizures and progressive neurological defects leading to early death. Treatment includes a high carbohydrate and low protein diet.
BioPAX SVG SBGN SBML PWML All files (.zip)

Creator: Ana Marcu

Created On: September 10, 2018 at 15:50

Last Updated: September 10, 2018 at 15:50

PW121690

Pw121690 View Pathway
disease

2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency

Mus musculus
2-Methyl-3-hydroxybutyryl CoA dehydrogenase deficiency (Hydroxyl-CoA dehydrogenase deficiency; MHBD) is a rare inborn disease of metabolism caused by a mutation in the HSD17B10 gene which codes for 3-hydroxyacyl-CoA dehydrogenase type-2. A deficiency in this enzyme results in accumulation of L-lactic acid in blood, spinal fluid, and urine; 2-ethylhydracrylic acid, 2-methyl-3-hydroxybutyric acid, and tiglylglycine in urine. Symptoms include cerebal atrophy, motor and mental retardation, overactivity and behavior issues, seizures and progressive neurological defects leading to early death. Treatment includes a high carbohydrate and low protein diet.
BioPAX SVG SBGN SBML PWML All files (.zip)

Creator: Ana Marcu

Created On: September 10, 2018 at 15:49

Last Updated: September 10, 2018 at 15:49